Page 107 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 107
Clinical Symposium - Bacterial infections in patients with liver disease Strauss 2
Chair:
Javier Fernandez, Spain
14:00 - 14:05 Introduction SCIENTIFIC PROGRAMME
14:05 - 14:30 Javier Fernandez, Spain
14:30 - 14:55
14:55 - 15:20 Advances in the pathogenesis and diagnosis of bacterial
15:20 - 15:30 infections in cirrhosis
Reiner Wiest, Switzerland
Multiresistant bacterial infections: mechanisms of resistance,
prevention strategies and clinical implications
Alex Soriano, Spain
Prognostic impact and treatment of bacterial infection in
critically-ill and non-critically-ill cirrhotic patients
Thierry Gustot, Belgium
Discussion
WHO-EASL Symposium Strauss 3
Chairs:
Markus Peck-Radosavljevic, Austria
Stefan Wiktor, Switzerland
14:00 - 14:15 WHO Prequalification of hepatitis serologic tests - A review
of the results of the analysis of the performance of hepatitis B
14:15 - 14:30 and C rapid and enzyme immunoassay tests and assessment of
14:30 - 14:45 manufacturers’ production quality
Anita Sands, Switzerland
Cost-effectiveness analysis of screening – NICE UK example.
An economic analysis of risk-based screening for hepatitis B
Natasha Martin, The United Kingdom
Providing testing services for persons who inject drugs and
linking them to care– Scottish example
David Goldberg, The United Kingdom
Vienna, Austria • April 22–26, 2015 107
Chair:
Javier Fernandez, Spain
14:00 - 14:05 Introduction SCIENTIFIC PROGRAMME
14:05 - 14:30 Javier Fernandez, Spain
14:30 - 14:55
14:55 - 15:20 Advances in the pathogenesis and diagnosis of bacterial
15:20 - 15:30 infections in cirrhosis
Reiner Wiest, Switzerland
Multiresistant bacterial infections: mechanisms of resistance,
prevention strategies and clinical implications
Alex Soriano, Spain
Prognostic impact and treatment of bacterial infection in
critically-ill and non-critically-ill cirrhotic patients
Thierry Gustot, Belgium
Discussion
WHO-EASL Symposium Strauss 3
Chairs:
Markus Peck-Radosavljevic, Austria
Stefan Wiktor, Switzerland
14:00 - 14:15 WHO Prequalification of hepatitis serologic tests - A review
of the results of the analysis of the performance of hepatitis B
14:15 - 14:30 and C rapid and enzyme immunoassay tests and assessment of
14:30 - 14:45 manufacturers’ production quality
Anita Sands, Switzerland
Cost-effectiveness analysis of screening – NICE UK example.
An economic analysis of risk-based screening for hepatitis B
Natasha Martin, The United Kingdom
Providing testing services for persons who inject drugs and
linking them to care– Scottish example
David Goldberg, The United Kingdom
Vienna, Austria • April 22–26, 2015 107
